Showing all 4 results
Daclatasvir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Dihydrochloride Salt Tablet, packed exclusively in highly secure, moisture-resistant heavy-gauge HDPE bottles or Alu-Alu blister strips to ensure the absolute chemical survival of the active virological agent.
Active Ingredient Strength Primary Clinical Function Daclatasvir Dihydrochloride USP/Ph.Eur. 60 mg The Standard Eradication Macrodose: The definitive, globally standardized daily therapeutic payload utilized for the vast majority of patients to achieve a Sustained Virologic Response (SVR12 – Clinical Cure). Daclatasvir Dihydrochloride USP/Ph.Eur. 30 mg The CYP3A4 Titration Unit: The strict, mandatory dose-reduction unit utilized for patients who are co-infected with HIV and taking strong CYP3A inhibitors (like Ritonavir or Atazanavir). Excipients Anhydrous Lactose / Microcrystalline Cellulose / Croscarmellose Sodium / Silicon Dioxide / Magnesium Stearate / Premium Polymeric Film (Opadry Green) Diluent / Densifier / Superdisintegrant / Glidant / Heavy Film-Coating (Engineered specifically utilizing advanced dissolution-enhancing matrices to ensure the Dihydrochloride salt separates perfectly in gastric fluid, guaranteeing maximum systemic bioavailability) *Pack Sizes: Heavy-Gauge HDPE Bottles of 28 (Optimized exactly for a 4-week supply in strict 12-week or 24-week curative regimens).
L- ornithine-L-aspartate tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical and physical stability of the highly hygroscopic amino acid salt.
Active Ingredient Strength Primary Clinical Function L-Ornithine L-Aspartate (LOLA) 150 mg / 250 mg Hepatology Maintenance Standard: Base therapeutic units for long-term chronic management of severe Non-Alcoholic Fatty Liver Disease (NAFLD), alcoholic hepatitis, and mild hyperammonemia. L-Ornithine L-Aspartate (LOLA) 500 mg Acute Detoxification Standard: High-efficacy adult therapy utilized for immediate ammonia reduction and the step-down management of Hepatic Encephalopathy following hospital discharge. Excipients Microcrystalline Cellulose / Crospovidone / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Opadry Moisture-Barrier Film Diluent / Superdisintegrant / Glidant / Film-Coating (Engineered specifically to lock out atmospheric moisture, preventing the heavy 500mg amino acid tablet from swelling, cracking, or prematurely degrading before it reaches the patient’s stomach) *Pack Sizes: 10×10 Blisters (Optimized specifically for strict, high-volume chronic hepatology dispensing regimens).
Ledipasvir & sofosbuvir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Dual-Active FDC Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles with specialized desiccants to ensure the absolute chemical survival of the complex antiviral APIs.
Active Ingredient Strength Primary Clinical Function Ledipasvir USP/Ph.Eur. 90 mg The NS5A Anchor: Potent inhibitor of viral assembly and secretion; highly effective against specific HCV genotypes. Sofosbuvir USP/Ph.Eur. 400 mg The NS5B Backbone: The globally recognized foundational DAA that forces viral RNA chain termination across multiple genotypes. Excipients Copovidone / Lactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Magnesium Stearate / Premium Opadry Film Binder / Diluent / Superdisintegrant / Lubricant / Film-Coating (Engineered specifically to solve the massive solubility differences between the highly soluble Sofosbuvir and the poorly soluble Ledipasvir, guaranteeing synchronized gastric release and peak systemic absorption) *Pack Sizes: Bottles of 28 (Optimized specifically for the strict 4-week dispensing intervals required for 8, 12, or 24-week curative regimens).
Ledipasvir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Solid-Dispersion Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical survival of the complex antiviral API.
Active Ingredient Strength Primary Clinical Function Ledipasvir USP/Ph.Eur. 90 mg Global Hepatology Standard: The definitive daily dose required to maintain constant, paralyzing pressure on the NS5A viral protein across the entire 12-to-24 week curative cycle. Excipients Copovidone / Lactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Magnesium Stearate / Premium Opadry Film Solubility Enhancer / Diluent / Superdisintegrant / Lubricant / Film-Coating (Engineered specifically utilizing Amorphous Solid Dispersion techniques with Copovidone to force the highly insoluble Ledipasvir to dissolve instantly in gastric fluid, guaranteeing maximum systemic bioavailability) *Pack Sizes: Bottles of 28 or 10×10 Blisters (Optimized specifically for strict 4-week dispensing intervals to match custom DAA combination regimens).
